New therapies to spur acute myeloid leukemia market growth

27 August 2013

Driven by a boost in new therapies entering the market, as well as an increasing number of acute myeloid leukemia (AML) cases among elderly patients, the AML market will grow significantly between 2012 and 2017, although lackluster results from clinical studies and cost-consciousness may continue to plague drug development, predicts research and consulting firm GlobalData.

According to the company’s new report, revenue for the AML market across the USA, France, Germany, Italy, Spain and the UK will increase from $151 million in 2012 to $430.7 million in 2017, representing a compound annual growth rate (CAGR) of 23.3%.

In 2012, the majority of the AML therapies sales were generated in the USA, which enjoyed a market share of $108.8 million, while sales in the top five European Union (5EU) countries were estimated to be around $42 million. By 2017, the AML market in the USA and the 5EU countries is expected to reach $324.4 million and $106.3 million in sales, respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK